Bayer has agreed to make a payment of $40m for settling claims over the alleged violations of the False Claims Act linked to three drugs, Trasylol, Avelox and Baycol, the US Department of Justice said in a press statement.
The settlement comes after a former Bayer employee, Laurie Simpson, filed two ‘whistleblower’ lawsuits against the company.
Go deeper with GlobalData
These litigations were filed under the qui tam or whistleblower provisions of the False Claims Act, which facilitate private citizens to file lawsuits against fake claims on behalf of the government.
Simpson alleged in a lawsuit filed in the District of New Jersey that Bayer paid kickbacks to physicians and hospitals to prompt them to use Trasylol and Avelox.
Simpson also alleged that the company sold these drugs for off-label usages that were not acceptable and essential.
See Also:
Additionally, the company was accused of downplaying Trasylol’s safety risks.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to the lawsuit, these actions of Bayer caused the submission of false claims to the Medicare and Medicaid Programs and also broke the laws in 20 states and the District of Columbia.
Trasylol is a medication utilised for controlling bleeding in some heart surgeries while Avelox is an antibiotic indicated for treating particular bacteria strains.
A second lawsuit filed by Simpson concerning a statin drug, Baycol, was eventually transferred to the District of Minnesota.
This litigation claimed that Bayer downplayed the risks of the drug causing rhabdomyolysis despite being aware of them.
The lawsuit also alleged that the company falsely prompted the Defense Logistics Agency into renewing some contracts linked to Baycol by distorting its efficacy against other statins.
Later on, the company withdrew Trasylol and Baycol from the market for safety reasons.
According to the settlement agreement, Bayer will make a payment of $38,860,555 to the US and $1,139,445 to the 20 states and the District of Columbia.
Simpson will get nearly $11m from the settlement proceeds.
Department of Justice Civil Division head, Principal Deputy Assistant Attorney General Brian Boynton said: “Simpson diligently pursued this matter for almost two decades.”
“The recovery highlights the critical role that whistleblowers play in the effective use of the False Claims Act to combat fraud in federal healthcare programmes.”
